Overview

Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients

Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
Elderly ITP patients have many underlying diseases, hormone contraindications and many adverse reactions during the use of hormones. TPO-RAs are oral small-molecule non-peptide drugs. Retrospective studies have shown that they have good efficacy and high safety in elderly patients. Therefore, this study is a prospective trial to evaluate TPO-RAs as the first-choice drug for the treatment of elderly ITP patients with contraindications to hormones, aiming to improve the efficacy-risk ratio of elderly patients
Phase:
Phase 4
Details
Lead Sponsor:
Wuhan Union Hospital, China
Collaborator:
Jiangsu Hengrui Pharmaceutical Co., Ltd.